These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 36571557)
81. Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registry. Zimmermann H; Nitsche M; Pott C; Reinke P; Babel N; Hermann RM; Hauser IA; Hahn D; Ritgen M; Pietschmann C; Klapper W; Anagnostopoulos I; Trappe RU; Ann Hematol; 2021 Aug; 100(8):2043-2050. PubMed ID: 33973053 [TBL] [Abstract][Full Text] [Related]
82. Risk factors and clinical outcomes of pediatric liver transplant recipients with post-transplant lymphoproliferative disease in a multi-ethnic Asian cohort. Huang JG; Tan MYQ; Quak SH; Aw MM Transpl Infect Dis; 2018 Feb; 20(1):. PubMed ID: 29071779 [TBL] [Abstract][Full Text] [Related]
83. EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort. Agrawal P; David KA; Chen Z; Sundaram S; Kim SH; Vaca R; Lin Y; Singer S; Malecek MK; Carter J; Zayac A; Kim MS; Reddy N; Ney D; Habib A; Strouse C; Graber J; Bachanova V; Salman S; Vendiola JA; Hossain N; Tsang M; Major A; Gandhi MK; Keane C; Bond DA; Folstad M; Chang J; Mier-Hicks A; Torka P; Rajakumar P; Venugopal P; Berg S; Glantz M; Goldlust SA; Matnani R; Kumar P; Ollila TA; Cai J; Spurgeon SE; Sieg AG; Cleveland J; Epperla N; Karmali R; Naik S; Smith SM; Rubenstein JL; Kahl BS; Chadburn A; Evens AM; Martin P Leuk Lymphoma; 2023 May; 64(5):1026-1034. PubMed ID: 36960939 [TBL] [Abstract][Full Text] [Related]
84. The Changing Epidemiology of Posttransplant Lymphoproliferative Disorder in Adult Solid Organ Transplant Recipients Over 30 Years: A Single-center Experience. Peters AC; Akinwumi MS; Cervera C; Mabilangan C; Ghosh S; Lai R; Iafolla M; Doucette K; Preiksaitis JK Transplantation; 2018 Sep; 102(9):1553-1562. PubMed ID: 29485513 [TBL] [Abstract][Full Text] [Related]
85. Association between Epstein-Barr virus seroconversion and immunohistochemical changes in tonsils of pediatric solid organ transplant recipients. Shapiro NL; Tang CG; Bhattacharyya N Laryngoscope; 2011 Aug; 121(8):1718-25. PubMed ID: 21792960 [TBL] [Abstract][Full Text] [Related]
93. EBV-specific cytotoxic T lymphocytes for refractory EBV-associated post-transplant lymphoproliferative disorder in solid organ transplant recipients: a systematic review. Liu JY; Zhang JM; Zhan HS; Sun LY; Wei L Transpl Int; 2021 Dec; 34(12):2483-2493. PubMed ID: 34510581 [TBL] [Abstract][Full Text] [Related]
94. Thoracic presentations of posttransplant lymphoproliferative disorders. Halkos ME; Miller JI; Mann KP; Miller DL; Gal AA Chest; 2004 Dec; 126(6):2013-20. PubMed ID: 15596707 [TBL] [Abstract][Full Text] [Related]
95. Epstein-Barr virus related post-transplant lymphoproliferative disorder prevention strategies in allogeneic hematopoietic stem cell transplantation. Lindsay J; Yong MK; Greenwood M; Kong DCM; Chen SCA; Rawlinson W; Slavin M Rev Med Virol; 2020 Jul; 30(4):e2108. PubMed ID: 32301566 [TBL] [Abstract][Full Text] [Related]
96. Primary Epstein-Barr virus infection, seroconversion, and post-transplant lymphoproliferative disorder in seronegative renal allograft recipients: a prospective cohort study. Hosseini-Moghaddam SM; Alhomayeed B; Soliman N; Weir MA; House AA Transpl Infect Dis; 2016 Jun; 18(3):423-30. PubMed ID: 27016725 [TBL] [Abstract][Full Text] [Related]
97. Hemophagocytic lymphohistiocytosis is a sign of poor outcome in pediatric Epstein-Barr virus-associated post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation. Ali S; AlThubaiti S; Renzi S; Krueger J; Chiang KY; Naqvi A; Schechter T; Punnett A; Ali M Pediatr Transplant; 2019 Feb; 23(1):e13319. PubMed ID: 30417487 [TBL] [Abstract][Full Text] [Related]
98. Burkitt post-transplantation lymphoma in adult solid organ transplant recipients: sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R-CHOP is safe and effective in an analysis of 8 patients. Zimmermann H; Reinke P; Neuhaus R; Lehmkuhl H; Oertel S; Atta J; Planker M; Gärtner B; Lenze D; Anagnostopoulos I; Riess H; Trappe RU Cancer; 2012 Oct; 118(19):4715-24. PubMed ID: 22392525 [TBL] [Abstract][Full Text] [Related]
99. The value of EBV DNA in early detection of post-transplant lymphoproliferative disorders among solid organ and hematopoietic stem cell transplant recipients. Wareham NE; Mocroft A; Sengeløv H; Da Cunha-Bang C; Gustafsson F; Heilmann C; Iversen M; Kirkby NS; Rasmussen A; Sørensen SS; Lundgren JD; J Cancer Res Clin Oncol; 2018 Aug; 144(8):1569-1580. PubMed ID: 29804164 [TBL] [Abstract][Full Text] [Related]
100. Characteristic pattern of chromosomal imbalances in posttransplantation lymphoproliferative disorders: correlation with histopathological subcategories and EBV status. Poirel HA; Bernheim A; Schneider A; Meddeb M; Choquet S; Leblond V; Charlotte F; Davi F; Canioni D; Macintyre E; Mamzer-Bruneel MF; Hirsch I; Hermine O; Martin A; Cornillet-Lefebvre P; Patey M; Toupance O; Kémény JL; Deteix P; Raphaël M Transplantation; 2005 Jul; 80(2):176-84. PubMed ID: 16041261 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]